FDA Accepts Filing of BridgeBio Pharma’s New Drug Application for an ATTR-CM Treatment

The biopharma company’s Phase 3 trial for its acoramidis product generated statistically significant results.

Source link
#FDA #Accepts #Filing #BridgeBio #Pharmas #Drug #Application #ATTRCM #Treatment